As one of the leading companies of the Turkish Pharmaceutical Industry for many years, Biofarma Pharmaceuticals is proudly continuing implementing policies with great emphasis on human and public health and with the principle of there can be no second quality in medicine.
Increasing its quality standards and targets day by day, Biofarma Pharmaceuticals is in long-term and solid R&D investments with a R&D structure it has created for the new products it will offer to Turkish Medicine and treatment.
The R&D Center carries out drug development activities with the machinery, equipment and devices in its powerful and high-tech Formulation and Analytical laboratories complying with national and international quality regulations. New drugs that are planned to be developed are determined by considering current treatment approaches and innovations. With the renewed R&D structure, product development processes are carried out in a highly efficient and controlled manner from the beginning of the project to the treatment phase.
The powerful and up-to-date pipeline that Biofarma R&D Center is working on includes CNS, cardiovascular, genito-urinary and gastrointestinal system preparations, as well as analgesic anti-inflammatory, antidiabetic, anti-infective and hormonal preparations.
Within this scope, products in solid, semi-solid and liquid forms are developed in the laboratories of the R&D Center in accordance with the current GMP and GLP requirements of the World Health Organization (WHO).
As a result of the importance given to R&D activities, patent applications continue and the number of projects applied to TÜBİTAK is increasing day by day.
Studies in the R&D Center are carried out by an expert staff who have received undergraduate, graduate and doctoral education in the fields of Chemistry and Pharmacy.